Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:08 2024-07-17 EDT			Pre-market 02:33:02
92.02 ^EUR	+0.11%		91.44	-0.63%

07:46am	Sanofi: positive data for hemophilia in children	CF
05:51am	Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms	MT

SANOFI : UBS sticks Neutral

January 09, 2023 at 05:39 am

UBS confirms his opinion on the stock and remains Neutral. The target price is reduced from EUR 97 to EUR 93.

Latest news about Sanofi

Sanofi: positive data for hemophilia in children	01:46am	CF
Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms	11:51pm	MT
Sanofi to invest $437 million in India global centre, double its workforce	07-17	RE
EU court criticizes Commission over handling of COVID vaccine contracts	07-17	RE
SANOFI : JP Morgan remains Neutral	07-16	ZD
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	07-12	RE
Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale	07-12	MT
Banks Including Goldman Sachs, Morgan Stanley Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale, Bloomberg Reports	07-12	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	07-10	RE
Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season	07-10	CI
SANOFI : Receives a Sell rating from Deutsche Bank	07-10	ZD
SANOFI : UBS reiterates its buy recommendation	07-09	CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday	07-09	MT
SANOFI : UBS maintains a Buy rating	07-09	ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours	07-08	MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy	07-08	CI
SANOFI : Jefferies maintains a Buy rating	07-08	ZD
SANOFI : Stifel slightly raises its target on the stock	07-08	CF
That's not so bad, is it?	07-08
Formation Biologics Inc. announced that it has received $372 million in funding from HongShan, Silicon Valley Venture Capital Corp., Sanofi	07-07	CI
Sector Update: Health Care Stocks Steady Premarket Friday	07-05	MT
Sector Update: Health Care	07-05	MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	07-05	CI
Sanofi's Consumer Health Unit Receives Interest from French State	07-04	MT
Bpifrance eyes investment in Sanofi's consumer health business	07-04	RE

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 03, 2024 at 04:01 pm

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am

Sanofi : In the hot seat

October 30, 2023 at 06:52 am

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

92.02 EUR

Average target price

108.6 EUR

Spread / Average Target

+17.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+2.52%	126B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : UBS sticks Neutral

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals